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The effects of nicotine, like those of other 
drugs with potential for abuse and dependence, 
are centrally mediated. The impact of nicotine 
on the central nervous system is 
neuroregulatory in nature, affecting biochemi- 
cal and physiological functions in a manner 
that reinforces drug-taking behavior. Dose- 
dependent neurotransmitter and neuroendo- 
crine effects occur as plasma nicotine levels 
rise when a cigarette is smoked. Circulating 
levels of norepinephrine and epinephrine in- 
crease, and the bioavailability of dopamine is 
altered as well. Among the neuroendocrine ef- 
fects are release of arginine vasopressin, p- 
endorphin, adrenocorticotropic hormone, and 
cortisol. Notably, several of these neurochemi- 
cals are psychoactive and/or known to modu- 
late behavior. Thus, affective states or cogni- 
tive demands may be favorably modified (at 
least temporarily) by nicotine intake. When 
nicotine is inhaled, the neuroregulatory effects 
just described are immediately available and 
the reinforcing effects of the drug are maxi- 
mized. On the other hand, nicotine gum and 
most other nicotine replacement vehicles in 
current use have a slower onset of action, re- 
sulting in less reinforcement value. Recent 
data suggest that smoking cessation rates may 
be optimized by tailoring the dose of nicotine 
replacement (for example, 2 or 4 mg of nico- 
tine gum) to the individual degree of nicotine 
dependence. In view of the dynamic interac- 
tions between the neuroregulatory effects of 
nicotine and a host of environmental condi- 
tions, nicotine replacement therapy is best car- 
ried out in combination with behavior modifi- 
cation techniques. 
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D rug dependence has been defined as sub- stance-seeking behavior involving a psychoac- 
tive agent that acts on the central nervous system 
[Il. All drugs with abuse liability have dose-depen- 
dent effects that can be discriminated from those of 
inactive substances, and these effects are centrally 
mediated. 
In rats, subcutaneous administration of nicotine 
has been shown to produce dose-dependent in- 
creases in cerebral glucose uptake, indicating 
heightened brain metabolic activity [2]. Similar 
changes in brain energy utilization have been ob- 
served in association with such drugs as cocaine. 
Central mediation of the effects of nicotine has been 
demonstrated by administration of mecamylamine, 
a nicotinic cholinergic blocker that crosses the 
blood-brain barrier. In contrast to the nicotine an- 
tagonist hexamethonium, which acts only peripher- 
ally, mecamylamine blocks increases in cerebral 
glucose uptake and produces some degree of neu- 
tralization of the effects of nicotine that are re- 
quired for maintaining dependence. 
Drugs of abuse are characteristically euphori- 
ants; these effects are dose dependent and centrally 
mediated. In studies of human subjects, nicotine 
has demonstrated dose-related euphoric effects 
similar to those of cocaine and morphine [3]. Nota- 
bly, however, the dose range at which nicotine is 
effective but not toxic is relatively narrow. This 
observation has important implications for the man- 
agement of nicotine dependence. 
Nicotine has been shown to be the psychoactive 
substance in cigarette smoke that accounts for both 
self-administration and reinforcement of drug- 
taking behavior. In one study, double-blind substi- 
tution of saline for nicotine resulted in discontinua- 
tion of self-administered injections by cigarette 
smokers [3]. Subsequently, when the subjects were 
allowed to choose between nicotine and placebo, 
they chose nicotine-demonstrating that nicotine 
functioned as a positive reinforcer. 
Drug dependence may be associated with toler- 
ance and physiologic withdrawal, although current 
concepts hold that these components are not essen- 
tial to the definition of dependence [l]. Nicotine 
withdrawal occurs with abrupt cessation or reduc- 
tion in nicotine intake in a person who has used the 
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drug daily for at least several weeks and is charac- nary fashion, or two high-dose cigarettes in rapid 
terized by the appearance within 24 hours of at succession, with deep inhalation (sufficient to pro- 
least four of the following signs [4]: duce nausea). 
l nicotine craving; 
l irritability, frustration, or anger; 
l anxiety; 
l difficulty concentrating; 
* restlessness; 
* decreased heart rate; 
* increased appetite. 
Nonetheless, apart from the first cigarette of the 
day or cigarettes smoked after prolonged depriva- 
tion, much smoking behavior seems to be prompted 
by independent environmental cues rather than the 
need to terminate or avoid withdrawal [5]. The ex- 
planation for this behavior may rest in specific, cen- 
trally mediated effects of nicotine that allow the 
smoker to gain temporary improvements in perfor- 
mance or affect. 
In this series of studies, nicotine levels increased 
by approximately 5-6 ng/mL with the low-dose cig- 
arette; by 20-25 ng/mL with the high-dose ciga- 
rette smoked in a normal manner; and by 60 ng/mL 
with the high-dose cigarettes smoked deeply [6,8]. 
As shown in Figure 2, dose-related increases were 
observed in plasma levels of arginine vasopressin 
and p-endorphin (although the assay used in this 
study had 50% co-reactivity with P-lipotropin). Ani- 
mal experiments have shown nicotine dose-related 
release of endogenous opioids in both hippocampal 
and hypothalamic sites [9]. In other words, not only 
do circulating endogenous opioids increase in re- 
sponse to nicotine, but release also occurs centrally. 
Dose-related increases in adrenocorticotropic 
hormone (ACTH) and cortisol were demonstrated 
as well, as shown in Figure 3 [7,8]. At the highest 
doses of nicotine, significant increases were also 
observed in growth hormone and prolactin, but thy- NEUROREGULATORY EFFECTS OF NICOTINE 
The impact of nicotine on the central nervous sys- 
tem is neuroregulatory in nature, with cascading 
effects on physiological and biochemical functions. 
The dose-related effects of nicotine on neurotrans- 
mitters and neuroendocrine responses therefore 
constitute a critical component of its pharmacologic 
action-effects that are responsible for both rein- 
forcement of nicotine self-administration and patho- 
physiological consequences. 
Effects on Catecholamines 
After a cigarette is smoked, circulating levels of 
catecholamines increase as plasma nicotine levels 
rise [5]. (Figure 1 shows the effects of smoking a 
typical cigarette [approximately 1 mg nicotine con- 
tent].) Even when there is only a modest increase 
in plasma nicotine level (as seen in individuals who 
have already smoked several cigarettes during the 
day), a profound increase in circulating norepineph- 
rine levels is observed. These increased levels of 
both nicotine and norepinephrine subsequently 
decay rapidly. Epinephrine levels rise in a dose- 
dependent fashion when a cigarette is smoked, and 
nicotine also alters the bioavailability of dopamine. 
All these effects are most pronounced following the 
first cigarette of the day. 
Effects on Hypophyseal Hormones 
Several studies by my colleagues and myself a 
decade ago focused on the response of pituitary hor- 
mones to various increases in nicotine levels [6-81. 
After overnight deprivation, subjects were in- 
structed to smoke either a low-dose cigarette in an 
ordinary fashion, a high-dose cigarette in an ordi- 
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Figure 1. Patterns of change in serum norepinephrine and epinephrine levels rela- 
tive to nicotine concentrations resulting from a single cigarette (approximately 1 mg 
nicotine content). Mean (+SEM) for 10 smokers who smoked following a 1.5.hour 
interval without cigarettes. 
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roid-releasing hormone, thyroid-stimulating hor- trol of sympathetic tone via norepinephrine media- 
mone, gonadotropin-releasing hormone, and vari- tion in the locus coeruleus, for example, may facili- 
ous sex hormones were not affected. tate ability to focus and concentrate. Central ace- 
BEHAVIORAL IMPLICATIONS 
tylcholine release has been shown to be involved in 
memory and task performance, thereby implicating 
Several of the neuroregulators that exhibit al- the cholinergic component of the nervous system. 
tered bioavailability in response to nicotine are In addition to its antidiuretic and vasoconstrictive 
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Figure 2. Baseline and peak levels of serum ar- 
ginine vasopressin and p-endorphin//S-lipotropin 
in subjects smoking a low-dose cigarette in ordi- 
nary fashion, a high-dose cigarette in ordinary 
fashion, or two high-dose cigarettes in rapid suc- 
cession, with deep inhalation (sufficient to pro- 
duce nausea in some cases). /3-LPH = 
P-lipotropin. Adapted with permission from [6] 
and [8]. 
Figure 3. Baseline and peak serum levels of 
adrenocorticotropic hormone and cortisol in 
subjects smoking a low-dose cigarette in ordi- 
nary fashion, a high-dose cigarette in ordinary 
fashion, or two high-dose cigarettes in rapid suc- 
cession, with deep inhalation (sufficient to pro- 
duce nausea in some cases). ACTH = 
adrenocorticotropic hormone. Adapted with per- 
mission from r/l and [8]. 
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with memory consolidation and retrieval. Endoge- 
nous opioids, such as /3-endorphin, not only potenti- 
ate vagal reflexes, decreasing respiratory rate and 
blood pressure by opposing the effects of catechol- 
amines, but are also associated with antinociception 
and anxiety reduction. Finally, the stimulation of 
cortisol by ACTH has been shown to modulate at- 
tention and stimulus discrimination and, in more 
recent research, to diminish the sensitivity of nico- 
tine receptors to subsequent stimulation. 
Examination of the psychological consequences 
of smoking suggests that affective states or cogni- 
tive demands can be modified in a favorable or 
adaptive manner, at least temporarily, by nicotine 
stimulation (Table I) [5]. By increasing central do- 
paminergic turnover, for example, nicotine can 
elicit or enhance “pleasure.” Increases in norepi- 
nephrine and P-endorphin may be implicated in 
these effects as well. 
Task performance may be facilitated by the ef- 
fects of nicotine on acetylcholine and norepineph- 
rine. Brief improvement in memory recall is likely 
related to effects on acetylcholine, norepinephrine, 
and perhaps vasopressin, whereas anxiety and ten- 
sion may be relieved by increases in p-endorphin. 
Dopamine and norepinephrine may be-involved in 
avoidance of weight gain (possibly because of a,re- 
duction in hunger), although an increasing body of 
evidence suggests that serotonin is also involved in 
these effects [ 101. Cholinergic activity mediates re- 
lief from nicotine withdrawal, and corticosteroid 
modulation of nicotinic receptor sensitivity may be 
involved as well. 
THERAPEUTIC INTERVENTIONS 
Role of Nicotine Replacement Therapy 
The administration of nicotine via cigarette 
smoking is particularly well suited to maximizing 
the neuroregulatory impact of the drug. Inhaled 
nicotine undergoes rapid absorption, with approxi- 
mately 25% of the inhaled drug reaching the brain 
within ‘7 seconds [l]. Nicotine from inhalation 
reaches the brain twice as fast as from intravenous 
administration. 
Inhaled nicotine produces a sharp rise in serum 
concentrations, with peak concentrations nearly 
always achieved by the time an individual has fin- 
ished smoking a cigarette (Figure 4). Conse- 
quently, the reinforcing effects of the drug are 
immediately available to the smoker and probably 
do not outlast the circumstances that prompted the 
smoking. Intranasal administration also results in 
an abrupt increase in serum concentrations and is 
currently -being investigated as a method of treat- 
ing nicotine dependence [ 111. 
In contrast to inhaled nicotine, nicotine gum (nic- 
TABLE I 
Reinforcement Consequences of Smoking and Putative 
Neuroregulatory Mechanisms 
Positive Reinforcement Negative Reinforcement 




Facilitation of task performance 
t acetylcholine 
f norepinephrine 




Reduction of anxiety and tension 
1‘ P-endprphin 




Relief from nicotine withdrawal 
t acetylcholine 
( t noncholinergic nicotinic activity?) 
- 
4dapted with permission from [5]. 
otine polacrilex) has a much slower onset of action, 
and its effects are sustained well beyond the cir- 
cumstances prompting nicotine self-administration 
[12]. Because peak concentrations are reached ap- 
proximately 0.5 hour after initial administration, 
less reinforcement value is realized than with ciga- 
rettes. Unlike cigarettes, therefore, nicotine gum 
has a low potential for abuse. 
According to one study, as the dose of nicotine 
gum is elevated, its perceived strength and similar- 
ity to cigarettes are increased correspondingly [13]. 
Since the 4 mg dose is associated with decreased 
patient acceptance and a higher incidence of side 
effects, compared with the 2 mg.dose, these consid- 
erations must be balanced against the greater relief 
of nicotine craving achieved with the higher dose. 
In a recent investigation, degree of nicotine de- 
pendence was used .to determine which nicotine 
replacement dose should be administered [14]. 
More-dependent smokers generally have a poorer 
prognosis than less-dependent smokers, but when 
the 4 mg dose was prescribed to high-dependency 
smokers, smoking cessation rates were comparable 
to those achieved by low-dependency smokers 
using the 2 mg dose (Figure 5). Similar findings for 
transdermal nicotine therapy suggest that the ben- 
efits of matching dosage to degree of dependency 
apply to all nicotine replacement vehicles. 
Role of Behavior Modification 
The neuroregulatory effects of nicotine are not 
fixed, but rather are dynamic-reflecting interac- 
tions with environmental conditions, history of nic- 
otine use, and ongoing behavior. A large number of 
internal and ‘external cues unrelated to nicotine 
dependence serve to prompt smoking. Conse- 
quently, nicotine replacement therapy, which fo- 
cuses mainly on relief of cigarette withdrawal, is 
best carried out in conjunction with behavior modi- 
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fication in order to strengthen the new habits re- 
quired to make the transition from smoker to non- 
smoker. 
In one of several reports on the issue, the use of 
nicotine gum alone was associated with a smoking 
cessation rate only slightly higher than that result- 
ing from the use of skills training alone [15]. When 
the two modalities were combined, however, the 
smoking cessation rate was better than for either 
modality in isolation, and the improvement was 
sustained into the follow-up period ~0.5 months 
after the start of treatment. In general, research 
has shown that pharmacological intervention is 
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Figure 4. Serum nicotine levels after administra- 
tion of nicotine via cigarette smoking, via nico- 
tine gum (2 or 4 mg nicotine polacrilex), or intra- 
nasally. Reprinted with permission from [U]. 
Figure 5. Smoking cessation rates in Iow- 
dependency smokers randomized to receive 2 
mg nicotine gum (NIC 2) or placebo (PLACJ ver- 
sus high-dependency smokers randomized to 
receive 2 or 4 mg (NIC 2 or 4) nicotine gum. 
Adapted with permission from 1141. 
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eludes social support and the inculcation of new 
skills [l]. Behavioral intervention is particularly 
useful for increasing adherence to pharmacological 
treatment. 
CONCLUSION 
Much remains to be learned about the 
neuroregulatory mechanisms by which nicotine 
exerts its effects. Current knowledge has been 
largely derived from studies in which nicotine ago- 
nists and antagonists have been administered 
under a variety of environmental conditions [9]. 
More information is needed on the timing and dura- 
tion of neuroregulator release as well as the pattern 
of neuroendocrine responses, relative to the history 
of nicotine use, varying environmental conditions, 
and mode of administration. In the future, newer 
research approaches-e.g., blood flow and meta- 
bolic studies using techniques such as positron 
emission tomography-may shed light on the par- 
ticular neuroregulatory pathways involved in 
human smoking. These technologies should facili- 
tate the specification of the neural locus of action of 
nicotine in relation to its behavioral and physiologi- 
cal effects. 
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